Publications
Topoisomerase 1 Inhibition in MYC-Driven Cancer Promotes Aberrant R-Loop Accumulation to Induce Synthetic Lethality
https://pennlab.ca/wp-content/uploads/2024/02/Figure.png 960 720 Penn Lab Penn Lab https://pennlab.ca/wp-content/uploads/2024/02/Figure.png
Computational pharmacogenomic screen identifies drugs that potentiate the anti-breast cancer activity of statins
https://pennlab.ca/wp-content/uploads/2023/05/Screen-Shot-2023-05-18-at-12.24.29-PM.png 757 671 Penn Lab Penn Lab https://pennlab.ca/wp-content/uploads/2023/05/Screen-Shot-2023-05-18-at-12.24.29-PM.png
The MYC oncoprotein directly interacts with its chromatin cofactor PNUTS to recruit PP1 phosphatase
https://pennlab.ca/wp-content/uploads/2022/03/m_gkac138figgra1.jpeg 520 391 Penn Lab Penn Lab https://pennlab.ca/wp-content/uploads/2022/03/m_gkac138figgra1.jpeg
MYC protein interactors in gene transcription and cancer
https://pennlab.ca/wp-content/uploads/2021/07/Lourenco_MYC_review.png 605 482 Penn Lab Penn Lab https://pennlab.ca/wp-content/uploads/2021/07/Lourenco_MYC_review.png
Identifying and Validating MYC:Protein Interactors in Pursuit of Novel Anti-MYC Therapies
https://pennlab.ca/wp-content/uploads/2023/05/MYC-Interactor-Identification-Pipeline-854x1024.webp 854 1024 Penn Lab Penn Lab https://pennlab.ca/wp-content/uploads/2023/05/MYC-Interactor-Identification-Pipeline-854x1024.webp
Mevalonate pathway inhibition slows breast cancer metastasis via reduced N-glycosylation abundance and branching
https://pennlab.ca/wp-content/uploads/2021/02/Rosemary_Dolichol.png 396 361 Penn Lab Penn Lab https://pennlab.ca/wp-content/uploads/2021/02/Rosemary_Dolichol.png
Statins as Anticancer Agents in the Era of Precision Medicine
https://pennlab.ca/wp-content/uploads/2020/11/Screen-Shot-2020-11-05-at-12.14.41-PM.png 717 688 Penn Lab Penn Lab https://pennlab.ca/wp-content/uploads/2020/11/Screen-Shot-2020-11-05-at-12.14.41-PM.png
Cyclic AMP‐hydrolyzing phosphodiesterase inhibitors potentiate statin‐induced cancer cell death
https://pennlab.ca/wp-content/uploads/2020/08/JL_cAMP-paper.png 952 562 Penn Lab Penn Lab https://pennlab.ca/wp-content/uploads/2020/08/JL_cAMP-paper.png
The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma
https://pennlab.ca/wp-content/uploads/2020/07/JL_t414-paper_cropped.png 295 211 Penn Lab Penn Lab https://pennlab.ca/wp-content/uploads/2020/07/JL_t414-paper_cropped.png- 1
- 2